Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383314199> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W4383314199 endingPage "605" @default.
- W4383314199 startingPage "596" @default.
- W4383314199 abstract "Summary Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer harboring MET exon 14 skipping alterations. The aims of this work were to investigate the potential for drug-drug interactions via cytochrome P450 (CYP) 3A4/5 or P-glycoprotein (P-gp) inhibition. In vitro studies were conducted in human liver microsomes, human hepatocyte cultures and Caco-2 cell monolayers to investigate whether tepotinib or its major metabolite (MSC2571109A) inhibited or induced CYP3A4/5 or inhibited P-gp. Two clinical studies were conducted to investigate the effect of multiple dose tepotinib (500 mg once daily orally) on the single dose pharmacokinetics of a sensitive CYP3A4 substrate (midazolam 7.5 mg orally) and a P-gp substrate (dabigatran etexilate 75 mg orally) in healthy participants. Tepotinib and MSC2571109A showed little evidence of direct or time-dependent CYP3A4/5 inhibition (IC 50 > 15 μM) in vitro, although MSC2571109A did show mechanism-based CYP3A4/5 inhibition. Tepotinib did not induce CYP3A4/5 activity in vitro, although both tepotinib and MSC2571109A increased CYP3A4 mRNA. In clinical studies, tepotinib had no effect on the pharmacokinetics of midazolam or its metabolite 1’-hydroxymidazolam. Tepotinib increased dabigatran maximum concentration and area under the curve extrapolated to infinity by 38% and 51%, respectively. These changes were not considered to be clinically relevant. Tepotinib was considered safe and well tolerated in both studies. The potential of tepotinib to cause clinically relevant DDI with CYP3A4- or P-gp-dependent drugs at the clinical dose is considered low. Study 1 (midazolam): NCT03628339 (registered 14 August 2018). Study 2 (dabigatran): NCT03492437 (registered 10 April 2018)." @default.
- W4383314199 created "2023-07-07" @default.
- W4383314199 creator A5023891526 @default.
- W4383314199 creator A5032045948 @default.
- W4383314199 creator A5035975526 @default.
- W4383314199 creator A5042855715 @default.
- W4383314199 creator A5045855346 @default.
- W4383314199 creator A5048131873 @default.
- W4383314199 creator A5054949108 @default.
- W4383314199 creator A5056787999 @default.
- W4383314199 creator A5061250423 @default.
- W4383314199 creator A5079355712 @default.
- W4383314199 creator A5085800652 @default.
- W4383314199 creator A5089035181 @default.
- W4383314199 date "2023-07-06" @default.
- W4383314199 modified "2023-10-16" @default.
- W4383314199 title "Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates" @default.
- W4383314199 cites W1482551660 @default.
- W4383314199 cites W2010427019 @default.
- W4383314199 cites W2013096789 @default.
- W4383314199 cites W2053652959 @default.
- W4383314199 cites W2091582819 @default.
- W4383314199 cites W2107763333 @default.
- W4383314199 cites W2138001494 @default.
- W4383314199 cites W2154905847 @default.
- W4383314199 cites W2161976213 @default.
- W4383314199 cites W2164113828 @default.
- W4383314199 cites W2399237148 @default.
- W4383314199 cites W2969837032 @default.
- W4383314199 cites W3003499321 @default.
- W4383314199 cites W3013025907 @default.
- W4383314199 cites W3140860453 @default.
- W4383314199 cites W3209291380 @default.
- W4383314199 cites W4225986451 @default.
- W4383314199 cites W4252867417 @default.
- W4383314199 doi "https://doi.org/10.1007/s10637-023-01378-z" @default.
- W4383314199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37415001" @default.
- W4383314199 hasPublicationYear "2023" @default.
- W4383314199 type Work @default.
- W4383314199 citedByCount "0" @default.
- W4383314199 crossrefType "journal-article" @default.
- W4383314199 hasAuthorship W4383314199A5023891526 @default.
- W4383314199 hasAuthorship W4383314199A5032045948 @default.
- W4383314199 hasAuthorship W4383314199A5035975526 @default.
- W4383314199 hasAuthorship W4383314199A5042855715 @default.
- W4383314199 hasAuthorship W4383314199A5045855346 @default.
- W4383314199 hasAuthorship W4383314199A5048131873 @default.
- W4383314199 hasAuthorship W4383314199A5054949108 @default.
- W4383314199 hasAuthorship W4383314199A5056787999 @default.
- W4383314199 hasAuthorship W4383314199A5061250423 @default.
- W4383314199 hasAuthorship W4383314199A5079355712 @default.
- W4383314199 hasAuthorship W4383314199A5085800652 @default.
- W4383314199 hasAuthorship W4383314199A5089035181 @default.
- W4383314199 hasBestOaLocation W43833141991 @default.
- W4383314199 hasConcept C109650736 @default.
- W4383314199 hasConcept C112705442 @default.
- W4383314199 hasConcept C126322002 @default.
- W4383314199 hasConcept C185592680 @default.
- W4383314199 hasConcept C2777477808 @default.
- W4383314199 hasConcept C3946865 @default.
- W4383314199 hasConcept C526171541 @default.
- W4383314199 hasConcept C62231903 @default.
- W4383314199 hasConcept C71924100 @default.
- W4383314199 hasConcept C98274493 @default.
- W4383314199 hasConceptScore W4383314199C109650736 @default.
- W4383314199 hasConceptScore W4383314199C112705442 @default.
- W4383314199 hasConceptScore W4383314199C126322002 @default.
- W4383314199 hasConceptScore W4383314199C185592680 @default.
- W4383314199 hasConceptScore W4383314199C2777477808 @default.
- W4383314199 hasConceptScore W4383314199C3946865 @default.
- W4383314199 hasConceptScore W4383314199C526171541 @default.
- W4383314199 hasConceptScore W4383314199C62231903 @default.
- W4383314199 hasConceptScore W4383314199C71924100 @default.
- W4383314199 hasConceptScore W4383314199C98274493 @default.
- W4383314199 hasIssue "4" @default.
- W4383314199 hasLocation W43833141991 @default.
- W4383314199 hasLocation W43833141992 @default.
- W4383314199 hasOpenAccess W4383314199 @default.
- W4383314199 hasPrimaryLocation W43833141991 @default.
- W4383314199 hasRelatedWork W1703321169 @default.
- W4383314199 hasRelatedWork W1996694250 @default.
- W4383314199 hasRelatedWork W2052588257 @default.
- W4383314199 hasRelatedWork W2142619379 @default.
- W4383314199 hasRelatedWork W2169462927 @default.
- W4383314199 hasRelatedWork W2324211119 @default.
- W4383314199 hasRelatedWork W2336887693 @default.
- W4383314199 hasRelatedWork W2897735866 @default.
- W4383314199 hasRelatedWork W2974708347 @default.
- W4383314199 hasRelatedWork W3190655411 @default.
- W4383314199 hasVolume "41" @default.
- W4383314199 isParatext "false" @default.
- W4383314199 isRetracted "false" @default.
- W4383314199 workType "article" @default.